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KEY POINTS 
1. Patients with EBV-associated T cells and NK cell lymphoproliferative diseases harbour 
large expansions of myeloid derived suppressor cells that may play a role in suppressing the 
antiviral T cell response. 
2. EBV infected T cells and NK cells persist in patients in large numbers following treatment. 
 
ABSTRACT   
Chronic active Epstein Barr virus (CAEBV) typically presents as persistent infectious 
mononucleosis-like disease and/or haemophagocytic lymphohistocytosis, reflecting ectopic 
EBV infection and lymphoproliferation of T and/or NK-cells. Clinical behaviour ranges from 
indolent, stable disease through to rapidly progressive, life-threatening disease. Whilst it is 
thought the chronicity and/or progression reflect an escape from immune control, very little is 
known about the phenotype and function of the infected cells versus co-resident non-
infected population, nor about the mechanisms that could underpin their evasion of host 
immune surveillance.   
To investigate these questions, we developed a multicolour flow cytometry technique 
combining phenotypic and functional marker staining with in-situ hybridisation for the EBER 
RNAs expressed in every infected cell. This allows the identification, phenotyping and 
functional comparison of infected (EBERPOS) and non-infected (EBERNEG) lymphocyte 
subset(s) in patients’ blood samples ex vivo. We have characterised CAEBV and HLH cases 
with monoclonal populations of discrete EBV-activated T-cell subsets, in some cases 
accompanied by EBV-activated NK-cell subsets, with longitudinal data on the infected cells’ 
progression despite standard steroid-based therapy. Given that cytotoxic CD8+ T-cells with 
relevant EBV antigen specificity were detectable in the blood of the best studied patient, we 
searched for means whereby host surveillance might be impaired. This revealed a unique 
feature in almost every CAEBV patient studied: the presence of large numbers of myeloid 
derived suppressor cells which exhibited robust inhibition of T-cell growth. We suggest that 
their influence is likely to explain the host’s failure to contain EBV-positive T/NK-cell 
proliferation.   
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INTRODUCTION 
Epstein-Barr virus is initially thought to infect oropharyngeal epithelium before colonising the 
B-cell system, initially as a growth-transforming infection with expression of the full set of latent 
cycle genes, followed by transition to an antigenically-silent latency within memory B-cells. 
Primary infection usually occurs during childhood and is almost always asymptomatic. Delay 
in primary infection until young adulthood can result in infectious mononucleosis (IM), an acute 
but self-resolving illness whose febrile symptoms appear to be a product of the host’s 
exaggerated cellular immune response. That response is initiated by natural killer cells (NK), 
followed by robust CD4+ and particularly CD8+ T-cell responses to lytic and latent cycle viral 
antigens 1,2.  However, when T-cell function is impaired, for example transplant recipients on 
immunosuppressive drugs, failure to control latent growth-transforming infection can lead to 
post-transplant B lymphoproliferative disease 3. 
By contrast, primary infection in a rare minority of individuals leads to a chronic, non-resolving 
condition termed chronic active EBV (CAEBV) encompassing many of the clinical features of 
IM such as fever, splenomegaly, hepatitis and lymphadenopathy.  In CAEBV, however, these 
symptoms are severe and persist for at least 3 months accompanied by very high EBV DNA 
load in the blood and extensive organ infiltration by EBV-infected cells. CAEBV can develop 
into a spectrum of clinical conditions. Patients with indolent disease can remain stable over 
many years, whilst others display a more rapidly progressive disease with serious 
complications including haemophagocytic lymphohistiocytosis (HLH), hepatic failure and 
gastrointestinal ulceration/perforation.  
In Western countries, CAEBV is thought to be predominantly associated with EBV infection of 
B-cells. Previously reported cases of B-cell CAEBV identified defective cytotoxic T 
lymphocytes (CTLs) 4 or NK-cells 5, in some cases linked to inactivating mutations in the 
perforin 6 or GATA2 gene 7; such impairment could explain the chronic nature of the disease. 
In contrast, CAEBV in South East Asia, Central and South America is predominantly 
associated with EBV infection of T-cells and NK-cells. In these patients, the clinical features, 
natural history and prognosis are associated with the phenotypic identity of the infected 
lineage; patients with T-cell CAEBV exhibit more aggressive disease and significantly inferior 
survival, while patients with NK-cell CAEBV more often have milder symptoms and a more 
favourable clinical outcome 8,9. However, NK-cell CAEBV seems to have a greater propensity 
(23.1%) for transformation into aggressive NK-cell leukaemia or extranodal NK/T-cell 
lymphoma 8-10. Thus the morbidity and mortality conferred by this clinically heterogeneous 
spectrum of EBV-associated lymphoproliferations is substantial. The high mortality is likely 
attributable to the paucity of effective treatment options. Immunomodulatory agents are largely 
ineffective and, while corticosteroids and other immunosuppressive agents temporarily 
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ameliorate clinical symptoms, patients usually succumb to progressive disease. Currently, 
allogeneic stem cell transplantation is the only established curative treatment 11-13.  
The pathogenesis of T/NK CAEBV is poorly understood. In contrast to B-cell CAEBV, patients 
with T/NK-cell CAEBV are not thought to have a pre-existing immune defect 10 yet infected 
cells persist in blood and tissues long-term. These EBV-infected T/NK-cells exhibit a Latency 
I/II viral gene expression profile (non-coding EBER RNAs, EBNA1 +/- LMP1 and LMP2a/TR) 
14 and should therefore elicit a T-cell response. This suggests that T-cell responses are either 
absent or in some way functionally inhibited. This hypothesis is supported by clinical 
experience in this context, whereby infusions of third-party EBV-specific CTLs have proven 
ineffective against progressive disease 15; suggesting an inhibitory mechanism is at play. 
To address the many issues raised by the different presentations of CAEBV and EBV-
associated LPDs, we developed a protocol, applicable to blood cell preparations ex-vivo, to 
inform patient management while helping to understand disease pathogenesis. Here we 
describe a protocol that combines EBER in-situ hybridisation, allowing visualisation and 
enumeration of EBV-infected cells, with cell surface and intracellular staining for a whole range 
of phenotypic and functional markers relevant to B, T or NK-cells and their subsets. This 
protocol was applied to five UK patients, all initially diagnosed as CAEBV or as HLH which 
were found to be EBV-related. Two proved to have B-cell infection; three had monoclonal T-
cell or NK-cell infections whose progression could be followed despite attempts at therapy. 
Surprisingly this same study revealed another unexpected but consistent feature of blood 
samples from T/NK CAEBV patients, the presence of large numbers of circulating myeloid-
derived suppressor cells (MDSCs) with the ability to suppress T-cell responses in in-vitro 
assays. This points to a potential link between MDSC-mediated T-cell inhibition and the 














Ethical approval  
This research received institutional approval from the University of Birmingham and studies of 
clinical material received ethical approval from the South Birmingham NRES Committee 
(07/H1208/62). All patients and healthy volunteers provided written informed consent in 
accordance with the Declaration of Helsinki.  
Flow cytometry 
PBMCs (5x106 cells) were stained using Fixable Viability Dye eFluor-450 or eFluor-780 
(ThermoFisher) for 30 min at 4°C. Cell surface staining was then performed with fluorophore-
conjugated antibodies (Table 1) for 30 min at 4°C. MDSCs were pre-incubated with purified 
human IgG (5 µg/ml) for 15 min at 4 °C prior to addition of mAbs. For intracellular staining, 
cells were fixed and permeabilised using the TrueNuclear™ Transcription Factor buffer Set 
(Biolegend) according to the manufacturer’s instructions then labelled with antibodies (Table-
1) for 30 min at room temperature. Fluorescence data was acquired using a LSR II or 
LSRFortessa X-20 (Becton Dickinson; BD) and analysed in FlowJo software version 7.6.5 
(Tree Star). 
FlowRNA for detection of EBV-encoded RNAs (EBERs) 
FlowRNA experiments were performed on 1-3x106 PBMC (PrimeFlow RNA, Thermo Fisher), 
according to the manufacturer instructions. A full description of the protocol can be found in 
supplementary information. Briefly, cells were stained using Fixable Viability Dye eFluor™-
450, then for cell surface markers (Table 1). Cells were fixed, permeabilised and intracellular 
staining performed in the presence of RNase inhibitors. Cells were fixed again then target 
RNA was hybridised using Target Probe sets (custom designed by PrimeFlow RNA, Thermo 
Fisher) for (i) EBER-1/2 and (ii) β2-microglobulin (B2M). Briefly, the probes were hybridised 
at 40°C for 3 hours, washed then subjected to sequential hybridization at 40°C using the 
‘PreAmplifier’, ‘Amplifier’ and fluorescent label (Type-1 probes, AlexaFluor®-647; Type-2 
probes, AlexaFluor®-488). Cells were acquired using a LSRII or LSRFortessa X-20 and 
analysed in FlowJo software version 10. 
Measurement of cytokines in plasma 
Plasma was collected following density centrifugation (Lymphoprep, Stemcell Technologies) 
of fresh EDTA blood samples. Plasma was immediately snap-frozen in liquid nitrogen and 
stored at -80C until use.  Cytokines in plasma (IL-1β, IL-4, IL-6, IL-10, IL-17A, IFNγ, GM-CSF, 
TNFα) were measured using a custom ProcartaPlex™ bead-based immunoassay 
(ThermoFisher) according to manufacturer’s instructions. Arginase-1 in plasma was measured 
by ProcartaPlex™ Singleplex immunoassay. Mean fluorescence intensity of each analyte was 
detected using a Luminex 200 instrument (R&D Systems, UK).   
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T lymphocyte proliferation assay 
Positive magnetic assisted cell sorting (MACS) using anti-human CD15 microbeads and 
MACS LS separation columns (Miltenyi Biotech) were used to isolate CD15+ G-MDSC from 
the PBMC. T lymphocytes were obtained from the PBMC by negative selection following 
removal of CD15+ cells. T-cells (2x105/well) were cultured in 96-well flat-bottom plates coated 
with anti-CD3 (OKT3; 3µg/ml) and anti-CD28 (2µg/ml) (eBioscience), in 200µl complete 
medium supplemented with 0.1% β-mercaptoethanol (ThermoFisher). Cells were incubated 
for 4 days at 37 °C, 5% CO2 and proliferation determined by 3H-thymidine (Perkin Elmer Life 
Sciences) incorporation using a TopCount NXT scintillation counter (Perkin Elmer). MDSC-
mediated suppression was determined by co-culture with T-cells. Results are expressed as a 
percentage of T-cell proliferation driven by CD3/28 ligation in the presence of MDSCs, relative 
to T-cell proliferation in their absence (100%). 
H&E staining of blood smears and PBMC cytospins 
Fresh blood was smeared on glass slides and freshly-isolated PBMC were spun onto glass 
slides, air-dried then fixed in 100% methanol for 1 minute. 
Statistical analysis 
Statistical tests used are indicated in relevant sections. All experiments where tests have been 
applied were performed on at least 3 donors. Tests were considered statistically significant if 




RESULTS.                                                                                                             
Set-up and Validation of Multicolour FlowRNA. 
To identify the lymphocyte subset infected by EBV we established a multicolour flow 
cytometry-based assay (FlowRNA) to simultaneously detect the abundantly expressed viral 
non-coding RNAs (EBER-1/2), present in every infected cell, together with lymphocyte subset 
markers CD3, CD4, CD8, CD19 and CD56 on 1-2 x 106 fresh mononuclear leukocytes 
(PBMC). The assay (Figure 1a), involved cell surface staining, cell fixation, permeabilization, 
intracellular staining then in-situ hybridisation (ISH) for the viral EBERs, and for Beta-2-
microglobulin (B2M) transcripts as a positive control. The cells were analysed by flow 
cytometry; lymphocytes were identified by Forward vs Side Scatter and CD14+ monocytes, 
dead cells and cell doublets were excluded from all subsequent analysis (Figure 1b). The 
assay was initially validated by adding decreasing numbers of EBV+/GFP+ Akata cells to EBV-
/GFP- Akata cells. The dual EBER+/GFP+ populations matched the input cell number and 
demonstrated assay sensitivity and specificity (Figure 1c). EBV-infected lymphocyte subsets 
were not identified in the blood of healthy EBV carriers (n=10), where the percentage of 
infected B-cells was below the threshold of detection (Figure 1d). However, the assay 
unambiguously identified EBV-infected subsets in previously frozen reference samples from 
patients with EBV-associated LPDs. In the case shown, EBV was detected in CD3+/CD8+ T-
cells with a small fraction detected in CD19+ B-cells (Figure 1d). In terms of virus load 
detectable by FlowRNA, provided at least 500 x 105 total patient lymphocytes were analysed 
by flow cytometry, we found the lowest viral load detected by the FlowRNA assay was 
approximately 8 x 104 virus copies/ml blood. 
Identification of EBV-infected lymphocytes by Multicolour FlowRNA.  
The clinical data for all five patients is summarised in Table 2 and expanded upon in 
Supplementary Data. Each patient presenting with EBV-associated LPDs had high EBV loads 
measured in whole blood, enabling the identification and enumeration of infected lymphocyte 
subsets directly from blood. The FlowRNA revealed clear populations of EBER-positive 
(EBERPOS) and EBER-negative (EBERNEG) lymphocytes; no other cell types, including myeloid 
cells, were EBERPOS. In patients 1 and 2, the EBERPOS cells were identified as CD19+ B-cells 
(Figure 2a), where approximately 1% of total B-cells were EBERPOS. Whilst this appears to be 
relatively low, detection of EBV in 1% of B-cells is remarkably high, equivalent to the number 
of EBV-infected B-cells in the blood of acute IM patients 16. In contrast, the numbers of EBV-
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infected B-cells in healthy carriers is on average one B-cell in 10,000 17, below the threshold 
of detection of the assay (Figure 1d).  
In patients 3 and 4, FlowRNA revealed EBV infection of the CD4+ T-cells (Figure 2b). The 
percentage of EBERPOS cells within the total CD4+ T-cell population was high for both patients; 
49% from patient 3 and 40% from patient 4. Patient 5 had a more complex profile of non-B-
cell infection. EBV was detected in at least 80% of total CD56+ NK-cells, 100% of which were 
CD56high (Figure 2b). EBV was also detected in CD4+, CD8+ T-cells, and CD19+ B-cells.  
Notably, the level of CD3 expression was down-regulated on the EBERPOS T-cells but not the 
EBERNEG T-cells, shown by mean fluorescence intensity (MFI) in Figure 2b. The MFI of CD3 
expression was slightly but consistently lower on the EBERPOS T cells from patient 3 and 5 
compared to the EBERNEG T cells; (patient 3 CD4+ T-cells CD3 MFI: EBERPOS 446 vs 
EBERNEG 614; patient 5 CD4+ T-cells CD3 MFI: EBERPOS 1240 vs EBERNEG 2019 and CD8+ 
T-cells CD3 MFI: EBERPOS 459 vs EBERNEG 1204). However, the MFI of CD3 expression on 
the EBERPOS CD4+ T-cells from patient 4 was significantly lower than the CD3 expression on 
the EBERNEG cells (MFI: EBERPOS 210 vs EBERNEG 1054). 
Clonality of the EBV-infected T-cells 
The EBV-associated T/NK-cell LPDs are considered monoclonal/oligoclonal proliferations of 
EBV-infected T/NK-cells due to the presence of a monoclonal virus 18. To extend these 
findings, we investigated T-cell receptor (TCR) clonality of the EBERPOS vs the EBERNEG CD4+ 
T-cells using a panel of mAbs directed against Vβ epitopes to delineate the TCRαβ repertoire. 
The TCR-BV usage in the EBERPOS CD4+ T-cells from patients 3 and 4, and the EBERPOS 
CD8+ T-cells from patient 5 revealed the presence of a monoclonal EBV proliferation; TCR-
BV8, TCR-BV12 and TCR-BV13.2 respectively (Figure 2c). However the EBERPOS CD4+ T-
cells from patient 5 were a clonally-diverse EBV-positive T-cell population. In contrast, the 
total EBERNEG CD4+ and CD8+ T-cells from each patient retained a heterogeneous spread of 
TCR-BV usage (Figure 2c). Single cell cloning of the EBERPOS and EBERNEG CD4+ T-cells 
from patient 4 and subsequent sequencing of the TCR V and V chains confirmed the TCR-
BV8 had identical CDR3 DNA sequences (Supplementary Data). 
Phenotype and Function of EBV-infected CD4+ T-cells 
The adaptability of FlowRNA enabled the simultaneous comparison of phenotype and function 
between EBERPOS and EBERNEG cells directly from patient blood, with matched lymphocyte 
subsets from healthy controls (n=6). We developed FlowRNA panels to examine markers of 
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T-cell subsets, activation, proliferative status and functional capacity to determine how EBV 
alters the phenotype and function of infected cells. We added CD45RA and CCR7 to 
discriminate between naïve (N: CD45RA+, CCR7+), central memory (CM: CD45RA-, CCR7+), 
effector memory (EM: CD45RA-, CCR7-) and terminally differentiated effector (TEMRA: 
CD45RA+, CCR7-) CD4+ T-cells; CD38 and Ki67 to examine activation and proliferative 
status; Foxp3 and CD25 to identify regulatory T-cells (Treg); plus IFNγ and TNFα to examine 
functional capacity.  
Interestingly, EBV infection appeared to be confined to memory T cells. The EBERPOS CD4+ 
T-cells from patients 3 and 4 expressed neither CD45RA nor CCR7, consistent with memory 
(Figure 3, top row). In contrast, the EBERNEG CD4+ T-cell population maintained N, CM, EM 
and TEMRA CD4+ T-cell subsets at similar ratios to those observed in healthy donors; 2 
representative donors shown (Figure 3a). These EBERPOS CD4+ T-cells also showed greater 
levels of activation and proliferation (CD38 and Ki67) than the EBERNEG CD4+ and healthy 
donor CD4+ T-cells. In patient 3, over 60% of EBERPOS cells expressed CD38, with at least 
15% of these co-expressing Ki67. In patient 4, the majority of EBERPOS cells expressed high 
levels of CD38 and co-expressed Ki67 (Figure 3b). Such findings suggest that EBV may be 
driving the activation and proliferation of infected cells.  
Examination of markers of Tregs, FoxP3 and CD25, revealed the EBERPOS cells were not 
Tregs. Furthermore, there was no evidence of increased numbers of Tregs in the EBERNEG 
population, compared to healthy donors (range 3 – 4%) (Figure 3c). However, EBV appeared 
to significantly alter the cytokine expression profile of infected cells in patients 3 and 4. Patient 
and healthy donor PBMCs were stimulated for 6 hours with PMA and ionomycin in the 
presence of brefeldin A, followed by intracellular cytokine staining. EBERPOS CD4+ T-cells 
exhibited remarkably different cytokine expression profiles. Whilst the majority (>70%) of 
EBERPOS cells from patient 3 produced IL-17A and IFNγ, the majority (>80%) of EBERPOS cells 
from patient 4 produced TNFα and/or IFNγ (Figure-3d) but little IL-4 and IL-17 (data not 
shown). In comparison, the EBERNEG CD4+ T-cells from both patients exhibited a cytokine 
expression profile broadly similar to that of healthy donor CD4+ T-cells (Figure 3d), with low 
abundance of IL-4 and IL-17A expressing cells (data not shown).  
To investigate whether the EBV infected CD4+ T cell clones were EBV specific, we tested 
their capacity to produce IFN in response to stimulation with a panel of HLA II-matched LCLs. 
In these preliminary analyses, no response was seen (data not shown), however further 
studies are required to determine the specificity of the EBV-infected CD4+ T cells.  
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EBV-infected T-cells are refractory to treatment 
We received blood from patient 3 following a diagnosis of HLH; the peripheral blood EBV load 
was 673,035 EBV DNA copies/ml and the EBERPOS cells accounted for 17% of their total 
CD4+ T-cells (Figure 4a). The patient was treated with corticosteroids and etoposide for the 
next 6 weeks, based on the HLH-2004 protocol 19. After this initial phase of therapy (8 weeks 
post-treatment), although the clinical and laboratory features of HLH had resolved, EBV load 
was consistently above 106 copies/ml and the proportion of EBERPOS CD4+ T-cells had 
increased more than 4-fold to 72% (Figure 4a). The total WBC counts and lymphocyte counts 
for the initial pre-treatment and post treatment samples were within the normal ranges and the 
counts were very similar (WBC: 4.1 cells/l vs 8.0 cells/l for pre- vs post-treatment; 
lymphocytes: 1.7 cells/l vs 1.6 cells/l for pre- vs post-treatment). The patient subsequently 
underwent an Alemtuzumab-based, reduced-intensity conditioned HSCT from a matched 
unrelated donor. Prior to transplant, the proportion of CD4+ T-cells infected with EBV 
remained high, at around 50%. Immediately following HSCT, EBV became undetectable in 
peripheral blood and remained so for >18 months post-transplant, aside from one episode of 
low-level reactivation where we confirmed the virus was exclusively in the B-cells; successfully 
treated with rituximab. However, the patient’s EBV DNA load began to rise rapidly at 21 
months post-transplant (from 34,950 to 684,750 copies/ml over a 3 week period). At 22 months 
post-transplant, we confirmed re-emergence of EBV-infected CD4+ T-cells in the peripheral 
blood (Figure 4b). The patient died approximately 6 weeks after this date. The CD4+ T-cell 
population comprised 40% of cells positive for TCR-BV8 (Figure 4c), suggesting that the 
original clone of EBV-infected CD4+ T-cells had persisted following transplantation and 
subsequently recrudesced, leading to disease relapse. 
Patient 4 initially presented with reactive lymphadenopathy, gastritis with benign histological 
appearances and high EBV load. After 6 months a gastric biopsy demonstrated a dense 
infiltration of mature T-cells, predominantly EBV+ CD4+ and an EBV load of 1,393,353 EBV 
DNA copies/ml. We received our initial sample at this point where EBERPOS cells accounted 
for 16% of their total CD4+ T-cells. He received steroid treatment followed by GDP 
(gemcitabine, dexamethasone, cisplatin) chemotherapy with some initial clinical improvement. 
Subsequent EBV load showed a climb to >8,000,000 EBV DNA copies/ml and the proportion 
of EBERPOS CD4+ T-cells increased 2.5-fold to 40% (Figure 4a). He was planned for SMILE 
(dexamethasone, methotrexate, ifosfamide, asparaginase, etoposide) chemotherapy but 
became acutely unwell and died due to bowel ischaemia. 
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Phenotype and Function of EBV-infected CD4+, CD8+ T+ and NK-cells from ANKL.  
At initial presentation with HLH, the vast majority of EBERPOS cells were CD56high NK-cells, 
with small additional populations of EBERPOS CD4+ and CD8+ T-cells. We therefore examined 
the phenotype and function of all infected subsets and their EBERNEG counterparts. As 
observed in patients 3 and 4, EBV infection of the CD4+ and CD8+ T-cells from patient 5 was 
restricted to cells without CD45RA and CCR7 expression, consistent with a memory 
phenotype (Figure 5a and 5e); the EBERNEG T-cells and matched healthy controls maintained 
the expected distribution of naïve and memory CD4+ T-cell populations. However the 
EBERPOS CD4+ T-cells completely lacked expression of the activation/proliferation markers 
CD38 and Ki67, with expression matching that of the EBERNEG CD4+ T-cells and matched 
healthy controls, suggesting EBV had not activated these infected cells. Furthermore, the 
EBERPOS CD8+ T-cells exhibited low levels of activation but little evidence of proliferation 
(Figure 5b and 5f).   
The EBERPOS CD4+ were not Tregs (CD25-, FoxP3-), and the proportion of Tregs within the 
EBERNEG or healthy control populations was not increased (Figure 5c and 5g). However, the 
majority of EBERPOS CD4+ T-cells expressed TNF (+/- IFN) with only a subset expressing 
neither cytokine (Figure 5d and 5h). All the EBERPOS CD8+ T-cells expressed IFN and TNF, 
or IFN alone. In comparison, over half the EBERNEG CD8+ T-cells expressed neither cytokine.  
Finally, we examined the same markers on the NK-cells. The EBERPOSCD56high NK-cells 
lacked expression of CD45RA and CCR7 (Figure 5i), unlike the EBERNEG patient and healthy 
donor NK-cells which expressed CD45RA alone. The entire populations of EBERPOS and 
EBERNEG NK-cells were activated (CD38+), although only the EBERPOS cells co-expressed 
Ki67 (Figure 5j), and the majority of EBERPOS and EBERNEG NK-cells expressed either TNF 
alone or in combination with IFN. In contrast, nearly 50% of healthy donor NK-cells expressed 
neither cytokine (Figure 5k). Initial examination of the CD56high NK cells revealed low level 
expression of CD16, however further analysis was precluded due to the rapid death of the 
patient. 
Myeloid-derived suppressor cells are expanded in the blood of patients, and potently 
inhibit T-cell responses. 
Analysis of fresh patient blood revealed large expansions of cells resembling neutrophils that 
co-purified with PBMCs following density centrifugation. Such cells were present at low 
abundance in healthy donor blood (n=6, <0.5% of PBMC) but outnumbered lymphocytes in 
 12 
three of the five cases (Figure 6a and 6b). These cells had nuclear morphology typical of cells 
undergoing granulopoiesis (Figure 6c) and expressed CD11b+, CD15+, CD16+ CD33+ but 
CD14- and HLA class II- (Figure 6d), confirming their identity as myeloid-derived suppressor 
cells of granulocyte lineage (G-MDSCs). 
Numerous growth factors and cytokines are thought to drive the expansion and suppressive 
activity of MDSCs. Luminex assays performed on patient plasma revealed the presence of 
high concentrations of GM-CSF, IL-1β, IL-6 and TNFα (Figure 6e) as well as IL-4, IFNγ and 
IL-10 (data not shown) relative to healthy individuals. Additional analysis of plasma from a 
banked collection of EBV-associated HLH patients (details provided in Supplementary 
material) also showed increased concentrations of these same cytokines. Furthermore, 
analysis of tissue culture medium from EBV-infected T cell clones established from CAEBV 
patients, but not the EBV uninfected T cell clones, also contained high concentrations of these 
cytokines (data not shown), suggesting the EBV-infected cells themselves are producing the 
cytokines observed in the patient plasma. Interestingly, we cloned EBV-specific CTLs from 
one patient that showed recognition of LMP1 epitopes, exhibited epitope-specific 
degranulation and ability to kill autologous cells presenting these epitopes (Supplementary 
Figure 1). 
MDSCs are thought to suppress effector T-cell growth and function through a number of 
mechanisms, including production of arginase-1. T-cells depend on L-arginine for proliferation 
and function are particularly sensitive to arginine-depletion by arginase-1. Luminex analysis 
showed an increase in the concentration of arginase-1 in patient plasma compared to healthy 
donors, where the concentration was below the level of detection (Figure 6f).  
MDSCs are highly labile and cryosensitive, therefore functional studies were performed on 
freshly-isolated patient MDSCs. Ex vivo MDSCs were co-cultured with allogeneic T-cells pre-
labelled with tritiated thymidine to analyse the growth of the T-cells in the presence of MDSCs. 
T-cell growth was increasingly suppressed when co-cultured with increasing MDSCs at T-cell: 
MDSC ratios from 1:0.125 up to 1:1, compared to T-cells cultured alone (Figure 6g). 
Furthermore, T-cells co-cultured with MDSCs at a 1:1 ratio exhibited significant growth 
inhibition when compared to culture with MDSCs from healthy individuals (p=0.0377) and to 






FlowRNA has significant clinical utility. The assay is particularly useful in confirming the 
differential diagnosis of an EBV-associated B-cell vs T/NK-cell LPD. This timely confirmation 
is important when considering targeted treatment options, monitoring treatment outcomes 
and identifying early relapse. This potential was clearly demonstrated for one patient who 
received HSCT due to EBV-infected CD4+ T-cells. Following HSCT, FlowRNA identified an 
expansion of EBV-infected B-cells, which was successfully treated with rituximab. The 
FlowRNA subsequently detected disease relapse arising from a re-emergence of the original 
EBERPOS CD4+ T-cell clone.   
FlowRNA has provided fundamental insights into disease pathogenesis.  Although we and 
others have previously reported infection of more than one lymphocyte subset in patients 
with T/NK-cell LPDs 10,20, it is not currently known if all infected subsets contribute to the 
disease.  Our data suggests perhaps not. When comparing the activation status of the 
EBERPOS CD4+ T-cells from patients 3, 4 and 5, the CD4+ T-cells from patient 5 showed a 
lack of activation, no difference in cytokine expression between the EBERPOS, EBERNEG and 
healthy donor CD4+ T-cells, and lack of clonality. In the context of multiple subset infection, 
these EBERPOS CD4+ T-cells may be bystander infections that contribute little to the overall 
disease pathogenesis and may represent early infection of progenitor cells before TCR 
rearrangement.  
Decreases in CD3 and TCR expression were revealed on all EBERPOS T-cells relative to 
their uninfected counterparts. As exemplified in patient 4, high level of activation is known to 
decrease cell-surface levels of CD3 and TCR, and indeed these cells co-expressed high 
levels of activation markers, CD38 and Ki67.  Interestingly, EBV infection appears to be 
restricted to CD45RA-/CCR7- memory T-cells. This is reminiscent of B-cell infection where 
EBV drives germinal centre-independent mutagenesis and clonal evolution of 
immunoglobulin genes in naïve B-cells to make them resemble memory B-cells 21. Perhaps 
EBV also drives TCR-independent differentiation from naïve to memory T-cells.  
Whilst the clonal EBERPOS CD4+ T-cells were consistent in their differentiation and activation 
status, their cytokine expression profile differed. Although we expected these differences 
would co-segregate with clinical presentation, this was actually not the case. Instead, the 
infected CD4+ T-cells exhibited differing cytokine expression profiles, irrespective of the 
disease. This suggests that EBV infection does not inhibit the functional differentiation of 
CD4+ T-cells. Interestingly, the uninfected CD4+ T-cells from patients and healthy donors 
were remarkably similar in phenotype and function, suggesting the uninfected cells were 
unaffected by the chronic inflammatory microenvironment.  
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Understanding how EBV-infected T- and NK-cells evade immune surveillance is of 
fundamental importance, particularly in the context of limited effective therapeutic options. 
MDSCs play a pivotal role in suppressing host immunity. Although most intensively studied 
in cancer, MDSCs are also generated as a result of chronic viral infection (including HCV, 
HIV and HBV), where they modulate the immunopathology and inhibit the antiviral T cell 
response 22-24. Although the evidence presented in this report demonstrates in vitro inhibition 
of T cell growth by the patient’s MDSCs, it does suggests that the MDSCs may be 
performing a similar role to that observed in the previously reported chronic infection 
scenarios. Thus, the MDSCs may be suppressing the antiviral T-cell response and enabling 
the persistence of the EBV-infected cells in the EBV-associated T cell and NK cell LPDs, 
although further investigation is required. In addition, previous reports of chronic infections 
have also demonstrated the virally infected cells secrete factors that drive the activation and 
expansion of MDSCs. This may be achieved, at least in part, by their expression of growth 
factors (GM-CSF, G-CSF) and pro-inflammatory cytokines (IL-1, IL-6, TNF-) 25,26. These 
growth factors and pro-inflammatory cytokines are often highly induced in chronic infection 
and stimulate the activation of myeloid progenitors, but may also drive the expansion and 
activation of MDSCs 27,28. Furthermore, the mechanisms of MDSC-mediated inhibition of T 
cell growth and function are known to include arginase-1, reactive oxygen (ROS) and 
nitrogen (NOS) species. These mechanisms can be blocked by inhibitors, resulting in the 
expansion of T cells in the presence of MDSCs. Although we were unable to perform these 
experiments ex vivo due to the lack of patient samples, given the raised concentrations of 
Arginase-1 in the patient plasma, it is highly likely these mechanisms play at least some role 
in the inhibition of T cell growth and function in these patients.  
A major finding of this study is that the EBV-infected T/NK-cells appeared to be refractory to 
treatment with the HLH2004 regimen containing etoposide, dexamethasone and cyclosporin 
A. For our evaluable patients, the number of EBV-infected cells increased in number whilst 
the total WBC and lymphocyte counts remained within the normal range and both the pre- 
and post-treatment samples were very similar in number. The large expansion of infected 
cells following treatment suggests that a subset of infected cells were resistant to the DNA 
damaging agent etoposide and were able to rapidly grow following the end of treatment. 
However, further studies are required to determine if the infected cells expanded throughout 
the course of treatment or indeed after treatment stopped. Corticosteroid treatment, usually 
dexamethasone or methylprednisolone, is a central component of commonly used protocols 
for EBV-associated HLH and CAEBV. The rationale for steroid-containing regimens is 
suppression of the transcription of T-cell effector cytokines. However, an important 
consequence is the loss of the effector T-cells from the circulation. These effector T-cells 
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may play a role in controlling the outgrowth of the EBV-infected cells and their loss may 
contribute to the expansion of infected cells following treatment. Therefore, one of two 
mechanisms could be restricting the outgrowth of the EBV-infected T/NK-cells; the MDSCs 
themselves or residual activity of endogenous EBV-specific CTLs. In either scenario, 
corticosteroids would disrupt this restriction, leading to unchecked expansion of infected 
T/NK-cells.  
Although only demonstrated in a small number of patients, these data appear to have major 
implications for therapy. The FlowRNA assay will therefore enable a thorough examination of 
how the number and function of EBV-infected T/NK cells impact on disease outcome and 
relapse following therapy and provide a better understanding of the implications of using 
agents such as etoposide and corticosteroids as first-line therapy. Secondly, the presence of 
MDSCs in other chronic viral infections have a significant impact on the disease outcome, 
particularly when considering the use of cell-based therapies. A thorough understanding of 
the role of MDSCs in EBV-associated HLH and CAEBV will enable a more targeted 
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 Antibody Fluorophore Clone Company 
Cell surface CD3 AF700 OKT3 eBioscience 
 CD3 APC SK7 BD 
 CD4 ECD T4 Beckman Coulter 
 CD8 AF488 HIT8a Biolegend 
 CD8 BV650 SK1 Biolegend 
 CD11b FITC ICRF44 Biolegend 
 CD14 Pacific blue M5E2 Biolegend 
 CD15 PE/Dazzle 594 SSEA-1 Biolegend 
 CD16 BV650 3G8 Biolegend 
 CD20 AF700 2h7 Biolegend 
 CD25 PE M-A251 Biolegend 
 CD33 PE P67.6 Biolegend 
 CD38 PE-Cy7 HB-7 Biolegend 
 CD45RA BV711 HI100 Biolegend 
 CD56 PE MEM0188 ThermoFisher 
 CD56 ECD N901 Beckman Coulter 
 CD197 (CCR7) PE G043H7 Biolegend 
 HLA-DR/DP/DQ PE-Cy7 Tu39 Biolegend 
 TCR/ PE B1 Biolegend 
Intracellular FoxP3 PE-Cy7 PCH101 eBioscience 
 Eomes PE WD1928 eBioscience 
 Perforin PE-Cy7 dG9 BD 
 Ki67 BV786 B56 BD 
 Granzyme B AF700 GB11 BD 
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Table 2. Clinical characteristics of patients with EBV-associated LPDs 
Pt Age/ 
gender 
History Presentation Diagnosis EBV PCR 
(copies/ml) 
Treatment Outcome 





CAEBV 3.8x105 None Alive, lost to 
follow-up 
















3 21/M Fevers, night 
sweats, weight 
loss 














4 54/M  Sub-acute illness 





















ANKL 1.99x106 Corticosteroids Death 
 
HLH, haemophagocytic lymphohistiocytosis: CAEBV, Chronic Active EBV; ANKL, Aggressive NK 
leukaemia; R-CHOP, Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, Prednisolone; FMT, 






























FIGURE 1. Multicolour FlowRNA protocol to identify the phenotype and function of the 
EBV-infected lymphocytes. (a) Mononuclear cells were isolated from peripheral blood, 
stained for lymphocyte lineage markers then fixed and permeabilised. Intracellular markers 
were then stained and the cells subject to fluorescence in situ hybridisation (FlowRNA) for 
the virally encoded EBERs and housekeeping cellular B2M. (b) EBV+/GFP+ Akata cells 
were added to EBV-/GFP- Akata cells at decreasing percentages (100%, 3%, 1%) and 
examined by FlowRNA to determine the sensitivity and specificity of the assay. (c) 
Lymphocytes were identified by forward vs side scatter and single cells were gated, dead 
and myeloid cells were excluded from further analysis. (d) The stained cells were examined 
by flow cytometry and plotted as CD19, CD3, CD4, CD8 and CD56 vs EBER to determine 
the subset of cells infected with EBV (dual positive). The upper panel shows a representative 
assay performed on blood of a healthy EBV carrier where no EBV-infected cells were 
detected. The lower panel shows a representative assay performed on the blood of a T/NK 
LPD patient and clearly shows CD3+, CD8+ and CD19+ lymphocyte populations expressing 
EBERs. The percentage of total CD19+ B-cells and total CD3+, CD8+ T-cells is given in the 
upper right hand quadrant. 
 
FIGURE 2. Identification of EBV-infected lymphocytes and clonality in the peripheral 
blood of patients. (a) Multicolour FlowRNA cytometric analysis of PBMCs from patients 1 
and 2 revealed EBV infection of CD19+ B-cells. (b) FlowRNA analysis of PBMC from 
patients 3, 4 and 5 revealed EBV infection of CD4+ T-cells from patient 3 and 4, and EBV 
infection of CD56high NK-cells, CD4+ and CD8+ T-cells. The analysis also revealed 
downregulation of CD3 expression in the EBERPOS across patients 3 to 5. The percentage of 
total lymphocyte subsets expressing EBERs is given in the upper right hand quadrant. (c) T-
cells were stained with a panel of 24 antibodies against the TCR-BV epitopes and analysed 
by flow cytometry. The % of T-cells expressing each TCR-BV are represented by Venn 
diagrams. For patients 3, 4 and 5, all EBERNEG T-cells exhibited polyclonal TCR-BV 
populations. However, the EBERPOS CD4+ T-cells from patients 3 and 4 exhibited a large 
monoclonal TCR-BV expansion (TCR-BV8 for patient 3 and TCR-BV12 for patient 4). In 
contrast, EBERPOS CD4+ T-cells from patient 5 exhibited a polyclonal TCR-BV population 
whereas the CD8+ T-cell exhibited a more focussed TCR-BV population (TCR-BV13.2). 
Key: TCR-BV usage.  
 
FIGURE 3. EBERPOS and EBERNEG cells exhibit differences in their phenotype and 
function. (a) EBERPOS and EBERNEG CD4+ T-cells from patients 3 and 4 were stained for 
CCR7 and CD45RA (top row), Ki-67 and CD38 (second row), Foxp3 and CD25 (third row) 
and TNFα and IFNγ (bottom row). Age-matched healthy donors were also analysed; two 
representative donors are shown. The analysis revealed the EBERPOS cell expressed 
markers consistent with memory T-cells, they were activated and proliferative, they were not 
Tregs and they expressed significant amounts of pro-inflammatory cytoines. In contrast, The 
EBERNEG CD4+ T-cells closely resembled the phenotype and function of the healthy donor 
CD4+ T-cells. 
 
FIGURE 4. EBV-infected CD4+ T-cells are resistant to conventional treatment 
regimens for CAEBV and HLH. (a) FlowRNA was performed on patient PBMCs to monitor 
outcome following treatment; both pre- and post-treatment samples are shown for patients 3 
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and 4. The percentage of EBERPOS CD4+ T-cells is shown in the upper right quadrant. The 
analyses revealed an increase in the number of EBV-infected CD4+ T-cells following 
treatment. (b) FlowRNA performed on PBMCs from patient 3, one month before HSCT (- 1 
month) and 16 months post-HSCT and shows a sustained loss of EBERPOS lymphocytes. 
However, analysis at 23 months post-HSCT revealed a significant population of EBERPOS 
CD4+ T-cells.  The percentage of EBERPOS CD4+ T-cells is shown in the upper right 
quadrant. (c) Analysis of the EBERPOS CD4+ T-cells identified at 23 months revealed the 
reappearance of the EBV-infected TCR-BV8 clone originally identified in the first sample.  
 
FIGURE 5. Phenotype and function of EBERPOS T and NK-cells from patient 5. 
FlowRNA analysis of EBERPOS and EBERNEG CD4+  and CD8+ T-cells from patient 5. PBMC 
were stained for CCR7 and CD45RA (top row), Ki-67 and CD38 (second row), Foxp3 and 
CD25 (third row) and TNFα and IFNγ (bottom row). Age-matched healthy donors were also 
analysed; one representative donor is shown. The phenotype and function of the EBERPOS 
CD4+ T-cells closely resembled that of the EBERNEG CD4+ T-cells and the healthy donors. 
The EBERPOS CD8+ T-cells were more activated and all expressed IFN and TNF. (c) Total 
NK-cells from patient 5 were stained for CD45RA and CCR7 (top row), Ki-67 and CD38 
(second row) and TNFα and IFNγ (bottom row). Analysis of NK-cells from one representative 
healthy donor is shown. All the EBERPOS NK-cells were highly activated and replicative, and 
they all expressed IFN.  
 
FIGURE 6. Granulocytic myeloid-derived suppressor cells are expanded in the blood 
of patients and potently inhibit T-cell responses. (a) Flow cytometric analysis of fresh 
patient PBMC by FSC vs SSC showed the presence of large granular cells (G-MDSCs), 
shown in blue; % of G-MDSCs to total PBMCs isolated is shown. A representative healthy 
donor is shown for comparison. (b) The % of G-MDSC is plotted with the mean compared to 
the mean from 10 healthy donors. A two-tailed Mann-Whitney test was used to compare 
groups. (c) Nuclear morphology of G-MDSCs (low density) and neutrophils (high density) 
revealed characteristic band cell/neutrophil morphology by H&E staining. (d) Flow cytometric 
analysis of the G-MDSC revealed expression of CD11b, CD15, CD16, CD33 but no 
expression of HLA II. Isotype controls (grey filled histogram) are shown. (e) Luminex assays 
for GM-CSF, IL-1, IL-6 and TNFα were performed upon patient plasma and compared to 
healthy donors. All patients had higher concentrations of these cytokines in their plasma 
than the healthy donors. Dashed horizontal line indicates the limit of accurate detection. (f) 
Luminex assay was used to determine the concentration of arginase-1 in the plasma of 
CAEBV and EBV-HLH patients, and healthy donors. Dashed horizontal line indicates the 
limit of accurate detection. (g) Inhibition of T-cell proliferation by MDSCs was measured 
following co-culture of T-cells with decreasing numbers of G-MDSCs (T:G-MDSC range 1:1 
to 1:0.125). The percentage T-cell proliferation in the presence of G-MDSCs is plotted 
relative to T-cells alone. Data shown is an average of 3 patients. (h) The inhibition of T-cell 
proliferation by G-MDSCs from patients and healthy donors at a T-cell:G-MDSC ratio of 1:1 
is plotted. Proliferation is shown relative to control (T-cells stimulated in the absence of 
MDSCs). In (g) and (h), a Kruskall-Wallis test was used to compare groups. In (b), (e) and 
(f), each patient is represented by a unique symbol as follows; patient 1 = +, patient 2 = x, 
patient 3 = o, patient 4 = Δ and patient 5 = □. 
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